公开(公告)号：US20240325409A1

公开(公告)日：2024-10-03

申请号：US18587048

申请日：2024-02-26

申请人： Enanta Pharmaceuticals, Inc.

发明人： Sean RAFFERTY ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Peilin XU ,  Samuel BARTLETT ,  Scott MITCHELL ,  Joseph D. PANARESE ,  Yat Sun OR

IPC分类号： A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

CPC分类号： A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US12103969B2

公开(公告)日：2024-10-01

申请号：US17266092

申请日：2018-09-25

申请人： Academia Sinica

发明人： Shie-Liang Hsieh ,  Tsung-Yu Tsai ,  An-Suei Yang ,  Chung-Ming Yu ,  Cheng-Yuan Peng

IPC分类号： C07K16/28 ,  A61P25/28 ,  A61P31/20 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61P25/28 ,  A61P31/20 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/77

摘要： Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

公开(公告)号：US12102654B2

公开(公告)日：2024-10-01

申请号：US17421717

申请日：2019-12-13

申请人： LIAONING GREATEST BIO-PHARMACEUTICAL CO. LTD.

发明人： Bo Gai ,  Chunyan Dou ,  Yi Zhang ,  Guoying Zhang

IPC分类号： A61K35/74 ,  A61K9/00 ,  A61P17/02 ,  A61P31/20 ,  C12N1/20 ,  C12R1/01

CPC分类号： A61K35/74 ,  A61K9/0014 ,  A61P17/02 ,  A61P31/20 ,  C12N1/205 ,  C12R2001/01

摘要： Isolated Rhodococcus ruber, a product derived from the Rhodococcus ruber (in particular, a product derived from the Rhodococcus ruber cell wall), a method for preparing the product derived from the Rhodococcus ruber, and use of the product derived from the Rhodococcus ruber in prevention and/or treatment of lichen planus. The product derived from the Rhodococcus ruber effectively reduce the erosion area of lichen planus and relieve pain.

公开(公告)号：US20240317808A1

公开(公告)日：2024-09-26

申请号：US18259538

申请日：2021-09-26

申请人： INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES

发明人： Xuemei Xu ,  Ting Zhang ,  Zhirong Wang ,  Baicheng Xia

IPC分类号： C07K14/005 ,  A61K39/00 ,  A61P31/20 ,  C12N15/70 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61P31/20 ,  C12N15/70 ,  C12N15/86 ,  A61K39/00 ,  A61K2039/5258 ,  A61K2039/58 ,  C07K2319/735 ,  C12N2710/14143 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2800/105 ,  C12N2800/22

摘要： The present invention relates to a human papillomavirus type 18 chimeric protein and the use thereof. Specifically, the present invention relates to a papillomavirus chimeric protein, which comprises or consists of an HPV type 18 L1 protein or a mutant of the HPV type 18 L1 protein, and a polypeptide from a HPV type 59 L2 protein inserted into the surface region of the HPV type 18 L1 protein or the mutant of the HPV type 18 L1 protein, wherein the amino acid sequence of the HPV type 18 L1 protein is as shown in SEQ ID No. 1, and the amino acid sequence of the HPV type 59 L2 protein is as shown in SEQ ID No. 2.

公开(公告)号：US12097251B2

公开(公告)日：2024-09-24

申请号：US17280805

申请日：2019-09-26

申请人： XIAMEN UNIVERSITY ,  XIAMEN INNOVAX BIOTECH CO., LTD.

发明人： Shaowei Li ,  Daning Wang ,  Jie Chen ,  Ying Gu ,  Jun Zhang ,  Ningshao Xia

IPC分类号： A61K39/12 ,  A61P31/20 ,  C07K14/015 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61P31/20 ,  C07K14/015 ,  C12N7/00

摘要： Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.

公开(公告)号：US20240309050A1

公开(公告)日：2024-09-19

申请号：US18274425

申请日：2021-09-01

申请人： SUN YAT-SEN UNIVERSITY ,  Sun Yat-sen University Cancer Center (SYSUCC)

发明人： Musheng ZENG ,  Cong SUN ,  Guokai FENG ,  Yinfeng KANG

IPC分类号： C07K14/005 ,  A61K9/51 ,  A61K39/00 ,  A61P31/20

CPC分类号： C07K14/005 ,  A61K9/5169 ,  A61P31/20 ,  A61K39/00 ,  A61K2039/5258 ,  A61K2039/55555 ,  A61K2039/575 ,  C12N2710/16222 ,  C12N2710/16223 ,  C12N2710/16234

摘要： Disclosed is a self-assembled nanoparticle containing a gHgL protein of an EB virus, a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gHgL protein and a first vector subunit, and the second polypeptide comprises a second vector subunit; the first vector subunit is 153-50A1, and the second vector subunit is 153-50B.4PT1; and the gHgL protein is linked to the first vector subunit through a linker. The gHgL protein of the EB virus is displayed on a surface of the self-assembled nanoparticle for the first time. The self-assembled nanoparticle has a larger particle size than the antigen (gHgL), a better antigen residence volume, and a thermal stability comparable to the antigen (gHgL). Moreover, since a larger number of gHgLs are displayed, the self-assembled nanoparticle can strongly stimulate more B cells and induce higher antibody titer.

公开(公告)号：US12091661B2

公开(公告)日：2024-09-17

申请号：US17714272

申请日：2022-04-06

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2320/31 ,  C12N2320/51 ,  C12N2320/53 ,  Y02A50/30 ,  C12N2310/321 ,  C12N2310/3521

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US12084661B2

公开(公告)日：2024-09-10

申请号：US17852888

申请日：2022-06-29

申请人： SUZHOU RIBO LIFE SCIENCE CO., LTD.

发明人： Hongyan Zhang ,  Shan Gao ,  Daiwu Kang

IPC分类号： C12N15/11 ,  A61P31/20 ,  C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1131 ,  A61P31/20 ,  A61K31/713 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2320/32

摘要： Provided are an siRNA for inhibiting expression of a Hepatitis B virus gene, and a pharmaceutical composition and conjugate containing the siRNA. Each nucleotide in the siRNA is an independently modified or unmodified nucleotide; the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A; the length of the nucleotide sequence A is the same as that of a nucleotide sequence as shown in SEQ ID NO: 1, and the number of the nucleotide differences is not more than three; the antisense strand comprises a nucleotide sequence B; and the length of the nucleotide sequence B is the same as that of a nucleotide sequence as shown in SEQ ID NO: 2, and number of nucleotide differences is not more than three.

公开(公告)号：US12070477B2

公开(公告)日：2024-08-27

申请号：US17019677

申请日：2020-09-14

申请人： KoBioLabs, Inc.

发明人： Gwang Pyo Ko ,  Hyun Ju You ,  Bo Mi Kwon

IPC分类号： A61K35/747 ,  A23C9/123 ,  A23L2/52 ,  A23L33/00 ,  A23L33/135 ,  A61P15/02 ,  A61P31/04 ,  A61P31/10 ,  A61P31/20 ,  C12N1/20 ,  C12R1/225

CPC分类号： A61K35/747 ,  A23C9/1234 ,  A23L33/135 ,  A23L33/40 ,  A61P15/02 ,  A61P31/04 ,  A61P31/10 ,  A61P31/20 ,  C12N1/205 ,  A23L2/52 ,  A23V2002/00 ,  A23V2400/11 ,  A23V2400/143 ,  A23V2400/145 ,  A23V2400/149 ,  C12R2001/225

摘要： The present invention relates to a novel Lactobacillus sp. isolation strain having an activity to inhibit the growth of vaginitis pathogens, and a pharmaceutical composition, a health functional food, and a cleansing product, comprising the strain as an active ingredient. Therefore, the present invention exhibits an effect of inhibiting the growth of Sneathia spp. pathogens associated with the infection with human papillomavirus (HPV) and the incidence of bacterial vaginitis, Gardnerella vaginalis as a vaginitis pathogen, and Candida albicans as a causative yeast of Candidal vaginitis, and an effect of recovering and maintaining the vaginal microflora, and thus can be used for the prevention and treatment of female vaginitis.

公开(公告)号：US20240254200A1

公开(公告)日：2024-08-01

申请号：US18541241

申请日：2023-12-15

申请人： APITBIO, INC.

发明人： Hyo Jeong HONG ,  Kyunghee JO ,  Jisu HONG ,  Young Jin CHOI ,  Jiwoo LEE

IPC分类号： C07K16/08 ,  A61K39/00 ,  A61P31/20

CPC分类号： C07K16/082 ,  A61P31/20 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76

摘要： The present invention relates to an antibody that specifically binds to a receptor binding motif of a hepatitis B virus preS1 antigen, and uses of the same.
The antibody of the present invention targets diverse genotypes of HBV, and can be thus usefully used in fields that require neutralization of HBV and entry inhibition and treatment of hepatitis B virus infection.